ak117
mAbexperimental
Clinical trial activity
19 trials · 9 clinical orgs · 0 marketing orgs
Phase 1
9
Phase 2
17
Phase 3
3
Phase 4
0
Earliest trial started Apr 25, 2020 (NCT04349969)
Timeline
Indications
Studied for
- Biliary Tract Neoplasms · Phase 2
- Breast Neoplasms · Phase 2
- Carcinoma, Hepatocellular · Phase 2
- Colorectal Neoplasms · Phase 2
- Esophageal Neoplasms · Phase 2
- Hodgkin Disease · Phase 1/Phase 2
- Leukemia, Myeloid, Acute · Phase 1/Phase 2
- Myelodysplastic Syndromes · Phase 2
- Neoplasm Metastasis · Phase 1/Phase 2
- Neoplasms · Phase 1
- Pancreatic Neoplasms · Phase 3
- Small Cell Lung Carcinoma · Phase 2
- Squamous Cell Carcinoma of Head and Neck · Phase 3
Mechanism of action
- Leukocyte surface antigen CD47INHIBITOR
CD47 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07264075 | Phase 3 | Jan 31, 2026 | Akeso Pharmaceuticals, Inc., Groupe Oncologie Radiotherapie Tete et Cou, Summit Therapeutics |
| NCT07245446 | Phase 2 | Oct 29, 2025 | Akeso Pharmaceuticals, Inc. |
| NCT06953999 | Phase 3 | May 14, 2025 | Akeso Pharmaceuticals, Inc. |
| NCT06789848 | Phase 2 | Feb 18, 2025 | Akeso Pharmaceuticals, Inc., The University of Texas, Dallas |
| NCT06642792 | Phase 1/Phase 2 (Phase 2) | Oct 31, 2024 | Akeso Pharmaceuticals, Inc. |
| NCT06601335 | Phase 3 | Oct 30, 2024 | Akeso Pharmaceuticals, Inc. |
| NCT06508606 | Phase 2 | Aug 1, 2024 | Sichuan University |
| NCT06387420 | Phase 1/Phase 2 (Phase 2) | Apr 29, 2024 | Akeso Pharmaceuticals, Inc. |
| NCT06196203 | Phase 2 | Feb 7, 2024 | Akeso Pharmaceuticals, Inc. |
| NCT05960955 | Phase 2 | Nov 13, 2023 | Akeso Pharmaceuticals, Inc. |
| NCT05382442 | Phase 2 | Jul 27, 2022 | Akeso Pharmaceuticals, Inc. |
| NCT05235542 | Phase 1/Phase 2 (Phase 2) | Jul 12, 2022 | Akeso Pharmaceuticals, Inc., Jiao Tong University |
| NCT05229497 | Phase 1/Phase 2 (Phase 2) | May 4, 2022 | Akeso Pharmaceuticals, Inc., Chinese Academy of Medical Sciences |
| NCT05227664 | Phase 2 | Mar 23, 2022 | Akeso Pharmaceuticals, Inc. |
| NCT05214482 | Phase 1/Phase 2 (Phase 2) | Jan 25, 2022 | Akeso Pharmaceuticals, Inc., Chinese Academy of Medical Sciences |
| NCT04980885 | Phase 1/Phase 2 (Phase 2) | Jul 31, 2021 | Akeso Pharmaceuticals, Inc. |
| NCT04900350 | Phase 1/Phase 2 (Phase 2) | Jun 18, 2021 | Akeso Pharmaceuticals, Inc., Soochow University |
| NCT04728334 | Phase 1 | Jan 27, 2021 | Akeso Pharmaceuticals, Inc., Fudan University |
| NCT04349969 | Phase 1 | Apr 25, 2020 | Akeso Pharmaceuticals, Inc. |
Showing 19 of 19 trials
Page 1 / 1
Organizations
Research & Development (9)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Akeso Pharmaceuticals, Inc. | For profit | 18 | 16 | 3 | 2020 |
| Chinese Academy of Medical Sciences | Academic/Hospital | 2 | 0 | 1 | 2022 |
| Fudan University | Academic/Hospital | 1 | 0 | 1 | 2021 |
| Groupe Oncologie Radiotherapie Tete et Cou | Academic/Hospital | 1 | 1 | 1 | 2026 |
| Jiao Tong University | Academic/Hospital | 1 | 0 | 1 | 2022 |
| Sichuan University | Academic/Hospital | 1 | 1 | 1 | 2024 |
| Soochow University | Academic/Hospital | 1 | 0 | 1 | 2021 |
| Summit Therapeutics | For profit | 1 | 0 | 1 | 2026 |
| The University of Texas, Dallas | Academic/Hospital | 1 | 1 | 1 | 2025 |
9 organizations
Page 1 / 1